Oravax-merieux Co.

Gopalan Soman

Thomas P Monath

William D Thomas, Jr

Harold Kleanthous

Farshad Guirakhoo

Samuel K Ackerman

Cynthia K Lee

Richard A Weltzin

Hitesh Bhagat

Jacques Pappo

William D Thomas

Ilene Sussman

Thomas Ermak

The invention provides methods for stabilizing recombinant Helicobacter urease by genetically modifying a urease amino acid. The stabilized urease is prevented from the molecular aggregation or activation (e.g., in vitro activation) characteristic of untreated urease.

Stabilization of helicobacter urease

A method for preventing the activation of inactive, recombinant Helicobacter pylori apourease is presented. The method comprises contacting the apourease with a compound that modifies a sulfhydryl or lysyl residue of the urease. The covalently modified apourease is prevented from molecular aggregation.

Method for preventing the activation of inactive, recombinant

Methods and compositions are provided for prophylactic and antibacterial therapy for Helicobacter, particularly for Helicobacter pylori, infection of humans. The immunogenic composition of the invention is composed of a plurality of multimeric complexes, each complex being composed of recombinant, enzymatically inactive Helicobacter pylori urease. Each multimeric complex is composed of six Urease A subunits and six Urease B subunits. Alternatively, the composition is composed of a mixture of multimeric complexes, wherein each multimeric complex in the mixture is composed of six Urease A subunits and six Urease B subunits or four Urease A subunits and four Urease B subunits.

Multimeric, recombinant urease vaccine

Growing community of inventors

Belmont, MA, United States of America

Gopalan Soman